Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib.
about
Therapeutic approaches in myelofibrosis and myelodysplastic/myeloproliferative overlap syndromesCritical appraisal of the role of ruxolitinib in myeloproliferative neoplasm-associated myelofibrosisAcute graft-versus-host disease: a bench-to-bedside update.Efficacy of ruxolitinib for myelofibrosis.Ruxolitinib: long-term management of patients with myelofibrosis and future directions in the treatment of myeloproliferative neoplasmsRuxolitinib: a review of its use in patients with myelofibrosis.Practical management of myelofibrosis with ruxolitinib.Safety considerations when treating myelofibrosis.MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosisRole of hematopoietic stem cell transplantation in patients with myeloproliferative disease.Janus kinase inhibitors and allogeneic stem cell transplantation for myelofibrosisImmunological basis for treatment of graft versus host disease after liver transplant.Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors.Combined nifuroxazide and SAT05f therapy reduces graft-versus-host disease after experimental allogeneic bone marrow transplantation.How we manage JAK inhibition in allogeneic transplantation for myelofibrosis.Allo-SCT for myelofibrosis: reversing the chronic phase in the JAK inhibitor era?Setting Appropriate Goals for the Next Generation of Clinical Trials in Myelofibrosis.Current Challenges in Stem Cell Transplantation in Myelofibrosis.Allogeneic hematopoietic stem cell transplantation for myelofibrosis and chronic myelomonocytic leukemia.Myelofibrosis-When Do We Select Transplantation or Non-transplantation Therapeutic Options?Blast-phase myeloproliferative neoplasms: risk factors and treatment approaches.New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment?Splenic pooling and loss of VCAM-1 causes an engraftment defect in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation.Recurrent Subcutaneous Sweet's Disease in a Myelofibrosis Patient Treated with Ruxolitinib before Allogeneic Stem Cell Transplantation.Usefulness of Low-Dose Splenic Irradiation prior to Reduced-Intensity Conditioning Regimen for Hematopoietic Stem Cell Transplantation in Elderly Patients with Myelofibrosis.Effect of conditioning regimens on graft failure in myelofibrosis: a retrospective analysis.Evaluation of Short-Term Ruxolitinib Tapering Strategy Before Allogeneic Stem Cell Transplantation for Primary Myelofibrosis Through the Transition of Serum Cytokines and Growth Factors.Treosulfan based reduced toxicity conditioning followed by allogeneic stem cell transplantation in patients with myelofibrosis.Risk factors and a prognostic model for postsplenectomy survival in myelofibrosis.A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms.Therapeutic effects of STAT3 inhibition by nifuroxazide on murine acute graft graft-vs.-host disease: Old drug, new use.Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation.A case-based discussion of clinical problems in the management of patients treated with ruxolitinib for myelofibrosis.Austrian recommendations for the management of primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis: an expert statement.JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosis.Safety and outcome of allogeneic stem cell transplantation in myelofibrosis.
P2860
Q26752940-31CF6D12-2552-425D-B94F-3468673FC1A6Q26996258-78698699-AA41-4047-99DA-F95023C4F4E1Q27687130-F33F571A-2E67-47CA-87D1-1D93E6BC6448Q33415489-08867B71-2C1C-4904-8DBE-BFFFF0E7252AQ33417217-8B1F9A4A-5D56-40E0-A9D5-E99D4AA89215Q33419865-D3DCB1FD-D362-4721-AFF9-95C4CD4D1E2DQ33428259-832AB2CE-7955-4B0D-9142-900C654042F3Q33432285-53A93D99-620A-4B3C-8BD7-234466906B13Q34047897-FB9EA90F-DE2E-4EFE-B902-C20044B5E9F8Q34625390-0F5A6F57-6E12-4354-BD1F-838F7332844DQ35735663-06D8F9CE-07CC-4BB9-8EE7-5AE1D8E28172Q37114440-C9B8B031-1F18-4C6C-AB3E-DF27EB65EBFFQ37272164-F2BD7925-F67F-4052-8FD6-A6D73402AE69Q37603497-9FD2F22A-338F-4827-900A-9A343E877C3BQ38254425-7CA2E0E9-FD18-4EBB-ACED-E26B72A9103DQ38349213-CB43A509-3B0A-4F11-AF0B-5E951C71FD25Q38567540-6BED5850-FAE8-4A20-8A8F-F9DD268C0CA3Q38569146-9E101D12-AAD5-426B-A2EA-AF667E34BFD7Q38603384-461947A2-65DD-40D7-B381-71F1C5636601Q38667263-D018ABA3-F5CD-462E-9D28-1D3295B96186Q38844669-1ACBC979-5B6B-44F5-832C-647DF7B9BDEFQ39307476-3A8DC583-6165-4604-8C75-F53B323E6099Q39357992-C69A48B8-768D-47A7-9955-1486F7F315ABQ40086569-1B0CDFC3-945C-4114-B0CE-82398FF5B2A8Q40453557-8FEC8B1F-31C3-4C6C-A936-E3CB692C72E5Q41519713-61ED0C86-0586-414D-BBC5-CC73ADD99E48Q41596288-C9A9A70F-9D70-4DDD-B3FD-9C9CA716CC2EQ41621459-3ACCC61D-A91E-41FF-8C9B-D9C7C80A652AQ48283014-32376AF8-4420-4C5E-84FA-E870285048ECQ48309941-3CDD35AA-F235-475F-BDBD-4528B0869A3BQ49222418-5653E2B6-ED3F-4655-A68A-6F4571CF0BA4Q49490860-3ECB8432-DB22-406A-973F-975FB8EC08D5Q51111145-E0DDB2AB-ECA9-4A41-B60E-676634DCBD87Q52813540-7F0312B3-80D4-4D53-875A-A47F1E801F9BQ54374933-8D2826E6-FFD9-42FF-AD82-1BBD3BC9265DQ55060741-0BAB4384-D6EC-40F7-8372-6F56CD85A766
P2860
Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Allogeneic hematopoietic cell ...... nd JAK2 inhibitor ruxolitinib.
@en
Allogeneic hematopoietic cell ...... nd JAK2 inhibitor ruxolitinib.
@nl
type
label
Allogeneic hematopoietic cell ...... nd JAK2 inhibitor ruxolitinib.
@en
Allogeneic hematopoietic cell ...... nd JAK2 inhibitor ruxolitinib.
@nl
prefLabel
Allogeneic hematopoietic cell ...... nd JAK2 inhibitor ruxolitinib.
@en
Allogeneic hematopoietic cell ...... nd JAK2 inhibitor ruxolitinib.
@nl
P2093
P2860
P356
P1476
Allogeneic hematopoietic cell ...... and JAK2 inhibitor ruxolitinib
@en
P2093
C Wickenhauser
D Niederwieser
P2860
P2888
P304
P356
10.1038/BMT.2013.173
P407
P577
2013-12-02T00:00:00Z